CellSeed Inc. develops regenerative medicine products. It operates through the Cell Sheet Regenerative Medicine and Intelligent Regenerative Medicine Support segments. The Cell Sheet Regenerative Medicine segment provides research, development, marketing, and sale of epithelial cell sheet for corneal and esophageal regeneration; regenerated cardiac patch to treat heart diseases; cell sheet for periodontal tissue regeneration; and regenerated cartilage sheet for the treatment of osteoarthritis. The Regenerative Medicine Support segment conducts research and development, manufacturing, and sales of temperature-responsive cell culture equipment. The company was founded by Yukio Hasegawa on May 9, 2001 and is headquartered in Tokyo, Japan.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company